WINT Windtree Therapeutics, Inc.

1.22
+0  (5%)
Previous Close 1.16
Open 1.15
Price To book 0.00
Market Cap 11.52M
Shares 9,439,000
Volume 70,409
Short Ratio 4.41
Av. Daily Volume 203,719

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 6, 2012 - under Discovery Laboratories, Inc.
Surfaxin
Respiratory Distress Syndrome
Phase 2b interim safety review completed April 11, 2017. Trial to continue to completion. Top-line data due mid 2017.
Aerosurf
Respiratory Distress Syndrome - premature infants 26 to 32 weeks
Announced October 25, 2016 that Phase 2a data to date has shown no durable response, requiring dosage to be increased to a third dosing group. Noted March 31, 2017 that top-line data due mid-2Q 2017. May 15, 2017 estimate only based on guidance of "mid-2Q".
Aerosurf
Respiratory Distress Syndrome - premature infants 26 to 28 weeks

Latest News

  1. Windtree Therapeutics and Tonix Pharmaceuticals on the Rise after FDA Clinical Trial News
  2. Windtree Announces Successful Completion of Second and Final AEROSURF® Phase 2b Clinical Trial Interim Safety Review
  3. ETFs with exposure to Windtree Therapeutics, Inc. : April 7, 2017
  4. Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017
  5. Windtree Therapeutics Reports Fourth Quarter 2016 Financial Results and Provides Key Business Updates
  6. Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study
  7. Windtree Therapeutics to Host a Conference Call and Webcast at 8:00 AM on Thursday, February 16, 2017 to Provide Clinical and Financial Updates
  8. Windtree Therapeutics Completes $10.5 Million Private Offering
  9. ETFs with exposure to Windtree Therapeutics, Inc. : January 3, 2017
  10. Is Windtree Therapeutics Inc (WINT) Going to Burn These Hedge Funds?
  11. Windtree Therapeutics Announces Upcoming Presentations at Hot Topics in Neonatology
  12. Windtree Therapeutics' AEROSURF® (lucinactant for inhalation) Phase 2a Data Presented at the 2016 International Congress of Union of European Neonatal and Perinatal Societies
  13. Windtree Therapeutics to Present at Stifel 2016 Healthcare Conference
  14. Windtree Therapeutics Preclinical Study Results Show Potential for KL4 Surfactant as Possible Medical Countermeasure to Radiation Exposure
  15. Windtree Therapeutics to Host Conference Call and Webcast on Tuesday, October 25, 2016 to Provide a Business Update
  16. Windtree Therapeutics Announces FDA Fast Track Designation for AEROSURF®
  17. Windtree Therapeutics, Inc. :WINT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 22, 2016
  18. Windtree Therapeutics Reports Second Quarter 2016 Financial Results and Provides Key Business Updates
  19. Windtree Receives $2.6 Million SBIR Grant to Support AEROSURF® Phase 2b Clinical Trial
  20. ETF’s with exposure to Windtree Therapeutics, Inc. : July 29, 2016